UNSPSC 51294519: Paroxetine acetate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent C19H20FNO3.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YPO0NTK49O, chemically known as piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, acetate (1:1), (3s,4r)-, but more generally known as paroxetine acetate, which bears US NIH Compound Identifier 9800501. Most nations, for tariff and trade purposes, schedule paroxetine acetate under HS 29349990 and SITC 51579.

As of Q4 2014, PAROXETINE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)O.C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.

UNSPSC 51294519 Paroxetine acetate is a Commodity code that in recent state and local procurement activity does not align with its nominal pharmaceutical product scope. The recent opportunities posted under this code instead reflect purchasing of emergency response medications (naloxone), safe drug deactivation systems, generic multi-source pharmaceuticals through cooperative purchasing vehicles, and pharmacy benefit program infrastructure — work that falls outside the specific antidepressant product this code names. State and local buyers have not posted solicitations for paroxetine acetate specifically; the code appears to be a mislabeling artifact within issuing bodies' procurement systems rather than an active purchasing category. Issuing bodies using this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering purchases on behalf of Minnesota Department of Administration and participating jurisdictions including Oregon).

Recent activity centers on three distinct procurement approaches: Seminole County posted an IFB (IFB60459723LAS, due July 26, 2023) for annual procurement of naloxone and drug deactivation systems through direct county purchasing; Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesaler channels; and Minnesota's MMCAP released an RFP (S1070000015802, due March 26, 2026) for multi-state generic pharmaceutical and OTC product supply through three authorized wholesalers. Geographic activity appears concentrated in the Southeast (Florida), South (Texas), and Upper Midwest (Minnesota and participating states), with no recent opportunities indicating sustained demand for the specific product this code names. The mismatch between the code and actual procurement content suggests that business development professionals should verify UNSPSC alignment directly with issuing bodies rather than rely on this code for targeting paroxetine acetate opportunities.